Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. more
Time Frame | FHTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -19.33% | -2.27% | -0.57% |
1-Month Return | -40.11% | -3.96% | 1.21% |
3-Month Return | -45.47% | -9.7% | 7.57% |
6-Month Return | -5.53% | -3.37% | 11.45% |
1-Year Return | -4.16% | 3.71% | 28.48% |
3-Year Return | -71.47% | 3.8% | 29.52% |
5-Year Return | -70.75% | 39.78% | 90.66% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 430.00K | 1.32M | 19.23M | 34.16M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":1.26,"profit":true},{"date":"2021-12-31","value":3.86,"profit":true},{"date":"2022-12-31","value":56.3,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 1.79M | 57.72M | 7.51M | 19.23K | 109.69M | [{"date":"2019-12-31","value":1.63,"profit":true},{"date":"2020-12-31","value":52.62,"profit":true},{"date":"2021-12-31","value":6.85,"profit":true},{"date":"2022-12-31","value":0.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (1.79M) | (57.28M) | (6.20M) | 19.21M | (75.53M) | [{"date":"2019-12-31","value":-9.33,"profit":false},{"date":"2020-12-31","value":-298.22,"profit":false},{"date":"2021-12-31","value":-32.26,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-393.23,"profit":false}] |
Gross Margin | (Infinity%) | (13322.09%) | (469.75%) | 99.90% | (221.15%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-13335.43,"profit":false},{"date":"2021-12-31","value":-470.22,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-221.37,"profit":false}] |
Operating Expenses | 51.08M | 68.96M | 102.05M | 136.37M | 142.06M | [{"date":"2019-12-31","value":35.96,"profit":true},{"date":"2020-12-31","value":48.54,"profit":true},{"date":"2021-12-31","value":71.84,"profit":true},{"date":"2022-12-31","value":95.99,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (51.08M) | (68.53M) | (100.73M) | (117.14M) | (107.91M) | [{"date":"2019-12-31","value":-5108400000,"profit":false},{"date":"2020-12-31","value":-6853100000,"profit":false},{"date":"2021-12-31","value":-10073400000,"profit":false},{"date":"2022-12-31","value":-11713700000,"profit":false},{"date":"2023-12-31","value":-10790600000,"profit":false}] |
Total Non-Operating Income/Expense | (89.00K) | (247.00K) | 61.00K | 13.93M | 24.30M | [{"date":"2019-12-31","value":-0.37,"profit":false},{"date":"2020-12-31","value":-1.02,"profit":false},{"date":"2021-12-31","value":0.25,"profit":true},{"date":"2022-12-31","value":57.33,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (51.13M) | (68.80M) | (101.32M) | (108.88M) | (94.20M) | [{"date":"2019-12-31","value":-5112800000,"profit":false},{"date":"2020-12-31","value":-6880000000,"profit":false},{"date":"2021-12-31","value":-10132000000,"profit":false},{"date":"2022-12-31","value":-10888200000,"profit":false},{"date":"2023-12-31","value":-9420000000,"profit":false}] |
Income Taxes | 540.00K | 979.00K | 1.91M | (8.26K) | 4.23M | [{"date":"2019-12-31","value":12.78,"profit":true},{"date":"2020-12-31","value":23.17,"profit":true},{"date":"2021-12-31","value":45.1,"profit":true},{"date":"2022-12-31","value":-0.2,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (51.67M) | (69.78M) | (103.23M) | (108.87M) | (98.43M) | [{"date":"2019-12-31","value":-5166800000,"profit":false},{"date":"2020-12-31","value":-6977900000,"profit":false},{"date":"2021-12-31","value":-10322600000,"profit":false},{"date":"2022-12-31","value":-10887374500,"profit":false},{"date":"2023-12-31","value":-9842600000,"profit":false}] |
Income From Continuous Operations | (51.13M) | (68.80M) | (101.32M) | (108.88M) | (103.21M) | [{"date":"2019-12-31","value":-5112800000,"profit":false},{"date":"2020-12-31","value":-6880000000,"profit":false},{"date":"2021-12-31","value":-10132000000,"profit":false},{"date":"2022-12-31","value":-10888200000,"profit":false},{"date":"2023-12-31","value":-10320600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (51.67M) | (69.78M) | (103.23M) | (108.87M) | (98.43M) | [{"date":"2019-12-31","value":-5166800000,"profit":false},{"date":"2020-12-31","value":-6977900000,"profit":false},{"date":"2021-12-31","value":-10322600000,"profit":false},{"date":"2022-12-31","value":-10887374500,"profit":false},{"date":"2023-12-31","value":-9842600000,"profit":false}] |
EPS (Diluted) | - | (6.27) | (2.70) | (2.62) | (2.34) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-627,"profit":false},{"date":"2021-12-31","value":-270,"profit":false},{"date":"2022-12-31","value":-262,"profit":false},{"date":"2023-12-31","value":-234,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
FHTX | |
---|---|
Cash Ratio | 4.71 |
Current Ratio | 4.77 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
FHTX | |
---|---|
ROA (LTM) | -20.45% |
ROE (LTM) | -470.38% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
FHTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 1.09 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | -0.09 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
FHTX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 13.47 |
P/B | 10.71 |
Price/FCF | NM |
EV/R | 3.65 |
EV/Ebitda | NM |
Foghorn Therapeutics Inc (FHTX) share price today is $5.3
Yes, Indians can buy shares of Foghorn Therapeutics Inc (FHTX) on Vested. To buy Foghorn Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in FHTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Foghorn Therapeutics Inc (FHTX) via the Vested app. You can start investing in Foghorn Therapeutics Inc (FHTX) with a minimum investment of $1.
You can invest in shares of Foghorn Therapeutics Inc (FHTX) via Vested in three simple steps:
The 52-week high price of Foghorn Therapeutics Inc (FHTX) is $10.25. The 52-week low price of Foghorn Therapeutics Inc (FHTX) is $2.7.
The price-to-earnings (P/E) ratio of Foghorn Therapeutics Inc (FHTX) is
The price-to-book (P/B) ratio of Foghorn Therapeutics Inc (FHTX) is 10.71
The dividend yield of Foghorn Therapeutics Inc (FHTX) is 0.00%
The market capitalization of Foghorn Therapeutics Inc (FHTX) is $343.57M
The stock symbol (or ticker) of Foghorn Therapeutics Inc is FHTX